Epidemiology and antifungal susceptibility of bloodstream Candida isolates in Quebec: Report on 453 cases between 2003 and 2005

Canadian Journal of Infectious Diseases and Medical Microbiology

Volumn 19, Issue 1, 2008, Pages 55-62

  St Germain, Guy ^a   Laverdière, Michel ^b   Pelletier, René ^c   René, Pierre ^d   Bourgault, Anne Marie ^e   Lemieux, Claude ^e   Libman, Michael ^d  

^a INSTITUT NATIONAL DE SANTÉ PUBLIQUE DU QUÉBEC   (Canada)

^b MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^c LAVAL UNIVERSITY   (Canada)

^d MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^e CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Antifungal resistance; Candidemia; Surveillance

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; CASPOFUNGIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; POSACONAZOLE; RAVUCONAZOLE; VORICONAZOLE;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC THERAPY; ANTIFUNGAL RESISTANCE; ARTICLE; CANDIDA ALBICANS; CANDIDA DUBLINIENSIS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA LUSITANIAE; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDEMIA; CHILD; DISEASE SURVEILLANCE; DRUG SENSITIVITY; FEMALE; FUNGUS IDENTIFICATION; HUMAN; IN VITRO STUDY; INCIDENCE; INFANT; INFECTION RATE; INFECTION RISK; INTENSIVE CARE UNIT; INTRAVASCULAR CATHETER; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; NEWBORN; NONHUMAN; PARENTERAL NUTRITION;

EID: 42249084884     PISSN: 17129532     EISSN: None     Source Type: Journal    
DOI: 10.1155/2008/634046     Document Type: Article

References (42)

1. Beck-Sagué C, Jarvis WR. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System. J Infect Dis 1993;167:1247-51.
2. Edmond MB, Wallace SE, McClish DK, Pfaller MA, Jones RN, Wenzel RP. Nosocomial bloodstream infections in United States hospitals: A three-year analysis. Clin Infect Dis 1999;29:239-44.
3. Golan Y, Wolf MP, Pauker SG, Wong JB, Hadley S. Empirical anti-Candida therapy among selected patients in the intensive care unit: A cost-effectiveness analysis. Ann Intern Med 2005;143:857-69.
4. Morgan J, Meltzer MI, Plikaytis BD, et al. Excess mortality, hospital stay, and cost due to candidemia: A case-control study using data from population-based candidemia surveillance. Infect Control Hosp Epidemiol 2005;26:540-7. (Erratum in 2005;26:675).
5. Zaoutis TE, Argon J, Chu J, Berlin JA, Walsh TJ, Feudtner C. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: A propensity analysis. Clin Infect Dis 2005;41:1232-9.
6. Almirante B, Rodríguez D, Park BJ, et al; Barcelona Candidemia Project Study Group. Epidemiology and predictors of mortality in cases of Candida bloodstream infection: Results from population-based surveillance, Barcelona, Spain, from 2002 to 2003. J Clin Microbiol 2005;43:1829-35.
7. Hajjeh RA, Sofair, AN, Harrison LH, et al. Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J Clin Microbiol 2004;42:1519-27.
8. Kao AS, Brandt ME, Pruitt WR, et al. The epidemiology of candidemia in two United States cities: Results of a population-based active surveillance. Clin Infect Dis 1999;29:1164-70.
9. Sandven P. Epidemiology on candidemia. Rev Iberoam Micol 2000;17:73-81.
10. Asmundsdóttir LR, Erlendsdóttir H, Gottfredsson M. Increasing incidence of candidemia: Results from a 20-year nationwide study in Iceland. J Clin Microbiol 2002;40:3489-92.
11. Diekema DJ, Messer SA, Brueggemann AB, et al. Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study. J Clin Microbiol 2002;40:1298-302.
12. Poikonen E, Lyytikäinen O, Anttila VJ, Ruutu P. Candidemia in Finland, 1995-1999. Emerg Infect Dis 2003;9:985-90.
13. Sandven P, Bevanger L, Digranes A, Gaustad P, Haukland HH, Steinbakk M. Constant low rate of fungemia in Norway, 1991 to 1996. The Norwegian Yeast Study Group. J Clin Microbiol 1998;36:3455-9.
14. Karlowsky JA, Zhanel GG, Klym KA, Hoban DJ, Kabani AM. Candidemia in a Canadian tertiary care hospital from 1976 to 1996. Diagn Microbiol Infect Dis 1997;29:5-9.
15. Laupland KB, Gregson DB, Church DL, Ross T, Elsayed S. Invasive Candida species infections: A 5 year population-based assessment. J Antimicrob Chemother 2005;56:532-7.
16. Macphail GL, Taylor GD, Buchanan-Chell M, Ross C, Wilson S, Kureishi A. Epidemiology, treatment and outcome of candidemia: A five-year review at three Canadian hospitals. Mycoses 2002;45:141-5.
17. Yamamura DL, Rotstein C, Nicolle LE, Ioannou S. Candidemia at selected Canadian sites: Results from the Fungal Disease Registry, 1992-1994. Fungal Disease Registry of the Canadian Infectious Disease Society. CMAJ 1999;23:493-9.
18. St-Germain G, Laverdière M, Pelletier R, et al. Prevalence and antifungal susceptibility of 442 Candida isolates from blood and other normally sterile sites: Results of a 2-year (1996 to 1998) multicenter surveillance study in Quebec, Canada. J Clin Microbiol 2001;39:949-53.
19. St-Germain G. [Étude de 100 souches de levures isolées de spécimens cliniques normalement stériles.] Bull Soc Fr Mycol Med 1988;17:309-12.
20. Al Mosaid A, Sullivan D, Salkin IF, Shanley D, Coleman DC. Differentiation of Candida dubliniensis from Candida albicans on Staib agar and caffeic acid-ferric citrate agar. J Clin Microbiol 2001;39:323-7.
21. Pfaller MA. Reference method for broth dilution antifungal susceptibility testing of yeasts. National Committee for Clinical Laboratory Standards. Approved standard M27-A2, 2nd edn, 2005.
22. Rex JH, Pfaller, MA, Walsh TJ, et al. Antifungal susceptibility testing: Practical aspects and current challenges. Clin Microbiol Rev 2001;14:643-58.
23. Odds FC, Motyl M, Andrade R, et al. Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species. J Clin Microbiol 2004;42:3475-82.
24. Pfaller MA, Messer SA, Boyken L, et al. Further standardization of broth microdilution methodology for in vitro susceptibility testing of caspofungin against Candida species by use of an international collection of more than 3,000 clinical isolates. J Clin Microbiol 2004;42:3117-9.
25. Rex JH, Cooper CR Jr, Merz WG, Galgiani JN, Anaissie EJ. Detection of amphotericin B-resistant Candida isolates in a broth-based system. Antimicrob Agents Chemother 1995;39:906-9.
26. Clinical and Laboratory Standards Institute. Quality control minimal inhibitory concentration (MIC) limits for broth microdilution and MIC interpretive breakpoints. Informational supplement M27-S2, 2nd edn, 2005.
27. Colombo AL, Nucci M, Park BJ, et al; Brazilian Network Candidemia Study. Epidemiology of candidemia in Brazil: A nationwide sentinel surveillance of candidemia in eleven medical centers. J Clin Microbiol 2006;44:2816-23.
28. Messer SA, Jones RN, Fritsche TR. International surveillance of Candida spp and Aspergillus spp: Report from the SENTRY antimicrobial surveillance program (2003). J Clin Microbiol 2006;44:1782-7.
29. Sandven P, Bevanger L, Digranes A, et al. Candidemia in Norway (1991 to 2003): Results from a nationwide study. J Clin Microbiol 2006;44:1977-81.
30. Pfaller MA, Diekema DJ; International Fungal Surveillance Participant Group. Twelve years of fluconazole in clinical practice: Global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida. Clin Microbiol Infect 2004;10(Suppl 1):11-23.
31. Pfaller MA, Diekema DJ, Gibbs, et al; Global Antifungal Surveillance Study. Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: An 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J Clin Microbiol 2007;45:1735-45.
32. Park BJ, Arthington-Skaggs BA, Hajjeh RA, et al. Evaluation of amphotericin B interpretive breakpoints for Candida bloodstream isolates by correlation with therapeutic outcome. Antimicrob Agents Chemother 2006;50:1287-92.
33. Cuenca-Estrella M, Rodriguez D, Almirante B, et al; the Barcelona Candidemia Project Study Group. In vitro susceptibilities of bloodstream isolates of Candida species to six antifungal agents: Results from a population-based active surveillance programme, Barcelona, Spain, 2002-2003. J Antimicrob Chemother 2005;55:194-9.
34. Goldman M, Pottage JC Jr, Weaver DC. Candida krusei fungemia. Report of four cases and review of the literature. Medicine (Baltimore) 1993;72:143-50.
35. Fidel PL Jr, Vazquez JA, Sobel JD. Candida glabrata: Review of epidemiology, pathogenesis, and clinical disease with comparison to C albicans. Clin Microbiol Rev 1999;12:80-96.
36. Krogh-Madsen M, Arendrup MC, Heslet L, Knudsen JD. Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient. Clin Infect Dis 2006;42:938-44.
37. Arthington-Skaggs BA, Warnock DW, Morrison CJ. Quantitation of Candida albicans ergosterol content improves the correlation between in vitro antifungal susceptibility test results and in vivo outcome after fluconazole treatment in a murine model of invasive candidiasis. Antimicrob Agents Chemother 2000;44:2081-5.
38. Rex JH, Nelson PW, Paetznick VL, Lozano-Chiu M, Espinel-Ingroff A, Anaissie EJ. Optimizing the correlation between results of testing in vitro and therapeutic outcome in vivo for fluconazole by testing critical isolates in a murine model of invasive candidiasis. Antimicrob Agents Chemother 1998;42:129-34.
39. Pfaller MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ. In vitro susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species to itraconazole: Global survey of 9359 isolates tested by Clinical and Laboratory Standards Institute broth microdilution methods. J Clin Microbiol 2005;43:3807-10.
40. Pfaller MA, Messer SA, Boyken L, et al. Use of fluconazole as a surrogate marker to predict susceptibility and resistance to voriconazole among 13,338 clinical isolates of Candida spp. Tested by clinical and laboratory standards institute-recommended broth microdilution methods. J Clin Microbiol 2007;45:70-5.
41. Pfaller MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ. In vitro susceptibilities of Candida spp. to caspofungin: Four years of global surveillance. J Clin Microbiol 2006;44:760-3.
42. Espinel-Ingroff A, Barchiesi F, Cuenca-Estrella M, et al. Comparison of visual 24-hour and spectrophotometric 48-hour MICs to CLSI reference microdilution MICs of fluconazole, itraconazole, posaconazole, and voriconazole for Candida spp: A collaborative study. J Clin Microbiol 2005;43:4535-40.